Interpreting Genome to Transform Patients' Lives: A Discussion on Genome Automation for Diagnosis
[Mississauga, ON.] Genome interpretation is the most complex bottleneck for clinical diagnosis, therapeutics and drug targets. Recent advancement of genome sequencing technologies are now providing labs with power to produce huge amounts of clinical genomic data. For clinics, interpretation of variants according to ACMG or other guidelines is crucial that requires massive cohort databases, regular updates, reanalysis and technological capacity to adopt numerous tertiary analysis. For all the clinical genomics labs in the world, technological availability and its adoption is critical to increase precision and ethnicity specific genetic insights.
Join us in this exciting discussion where Dr. Mohammed Uddin Dafil a Canadian geneticist who founded GenomeArc will discuss the current technologies that are critical in interpreting genomes for clinical impact. His talk will include the application of
- long read sequencing,
- recent pangenome initiatives, and
- the application of artificial intelligence for better clinical interpretation of genomes.
Canadian Broadcast: 9am, July 19th, 2023, Toronto
Register: https://docs.google.com/forms/d/e/1FAIpQLSd9oF2mkH8cle8WLS_LiyOFW11_kkSGfj05jZ2YkP63CcUjHg/viewform
GenomeArc Inc. is a biotech company on clinical genetics and drug discovery headquartered in Mississauga, Ontario. The company began its journey in 2021, GenomeArc develops artificial intelligence integrated solutions for genetic diagnosis and genomic drug development solutions for rare genetic disorders and pan cancer. As a research-oriented biotech company, GenomeArc brings new insights into rare diseases, cancer diagnosis, and therapeutics through genome analysis. The GenomeArc team is constantly innovating technologies to solve phenotypic complexities in genetic variations for rapid intervention. As a global company, our aim is to make efficient and accurate genome medicine technologies accessible for all healthcare systems.
See more Blogs: